Bacille Calmette-Guerin (BCG) vaccine for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  El Matary, Wael ^a   Yap, Jason ^a   Gilmour, Susan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BCG VACCINATION; CLINICAL PROTOCOL; CLINICAL RESEARCH; CROHN DISEASE; DATA ANALYSIS; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; REMISSION; REVIEW;

EID: 77950159996     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008029     Document Type: Review

References (12)

1. Akobeng 2004 Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2004, Issue 1. [Art. No.: CD003574. DOI: 10.1002/14651858.CD003574.pub2]
2. Alfadhli 2005 Alfadhli AAF, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2005, Issue 1. [Art. No.: CD003459. DOI: 10.1002/14651858.CD003459.pub2]
3. Benchimol 2008 Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008 Apr 16, Issue (2): CD006792.[Art. No.: CD006792. DOI: 10.1002/ 14651858.CD006792.pub2]
4. Bergman 2006 Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23(7): 841-55.
5. Buller 2001 Buller HA. Objectives and outcomes of the conventional treatment of pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2001;33: S11-S18.
6. Hanauer 2006 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al.Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.. Gastroenterology 2006;130(2):323-33. [PUBMED: 16472588]
7. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60..
8. Higgins 2008 Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008).. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org., 2008., 2008.
9. Rousseau 2008 Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatric Allergy & Immunology. England, 2008; Vol. 19, issue 5:438-48. [MEDLINE: 18167158; REFWORKS: ID: 613]
10. Sandborn 1998 Sandborn WJ, Sutherland LR, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 1998, Issue 3. [Art. No.: CD000545. DOI: 10.1002/ 14651858.CD000545]
11. Sandborn 2007 Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al.Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38. [PUBMED: 17470824]
12. Szewczuk 1992 Szewczuk MR, Depew WT. Evidence for T lymphocyte reactivity to the 65 kilodalton heat shock protein of mycobacterium in active Crohn's disease. Clinical & Investigative Medicine - Medecine Clinique et Experimentale. CANADA, 1992; Vol. 15, issue 6: 494-505. [MEDLINE: 1286531; REFWORKS: ID: 610]